NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
June 26, 2022
Note 1: Company and Industry Information
The Company designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. Semiconductor manufacturing, our customers’ business, involves the complete fabrication of multiple dies or integrated circuits on a wafer. This involves the repetition of a set of core processes and can require hundreds of individual steps. Fabricating these devices requires highly sophisticated process technologies to integrate an increasing array of new materials with precise control at the atomic scale. Along with meeting technical requirements, wafer processing equipment must deliver high productivity and be cost-effective.
The Company sells its products and services primarily to companies involved in the production of semiconductors in the United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan.
The semiconductor industry is cyclical in nature and has historically experienced periodic downturns and upturns. Today’s leading indicators of changes in customer investment patterns, such as electronics demand, memory pricing, and foundry utilization rates, may not be any more reliable than in prior years. Demand for the Company’s equipment can vary significantly from period to period as a result of various factors including, but not limited to economic conditions; supply, demand, and prices for semiconductors; customer capacity requirements; and the Company’s ability to develop and market competitive products. For these and other reasons, the Company’s results of operations for fiscal years 2022, 2021, and 2020 may not necessarily be indicative of future operating results.
Reclassification: Certain amounts for the fiscal year 2021 footnotes have been reclassified to conform to the fiscal year 2022 presentation.
Note 2: Summary of Significant Accounting Policies
The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that could affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience and on various other assumptions it believes to be applicable and evaluates them on an ongoing basis to ensure they remain reasonable under current conditions. Actual results could differ significantly from those estimates.
Revenue Recognition: The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process, (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.
Identify the contract with a customer. The Company generally considers documentation of terms with an approved purchase order as a customer contract provided that collection is considered probable, which is assessed based on the creditworthiness of the customer as determined by credit checks, payment histories, and/or other circumstances.
Identify the performance obligations in the contract. Performance obligations include sales of systems, spare parts, and services. In addition, customer contracts contain provisions for installation and training services which have been deemed immaterial in the context of the contract.
Determine the transaction price. The transaction price for the Company’s contracts with its customers consists of both fixed and variable consideration provided it is probable that a significant reversal of revenue will not occur when the uncertainty related to variable consideration is resolved. Fixed consideration includes amounts to be contractually billed to the customer while variable consideration includes estimates for discounts and credits for future usage which are based on contractual terms outlined in volume purchase agreements and other factors known at the time. The Company generally invoices customers at shipment and for professional services either as provided or upon meeting certain milestones. Customer invoices are generally due within 30 to 90 days after issuance. The Company’s contracts with customers typically do not include significant financing components as the period between the transfer of performance obligations and timing of payment are generally within one year.
Allocate the transaction price to the performance obligations in the contract. For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to historical discounting trends for products and services and pricing practices in different geographies.
Recognize revenue when or as the Company satisfies a performance obligation. Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.
Lam Research Corporation 2022 10-K 45
Inventory Valuation: Inventories are stated at the lower of cost or net realizable value using standard costs that approximate actual costs on a first-in, first-out basis. Finished goods are reported as inventories until the point of title transfer to the customer. Unless specified in the terms of sale, title generally transfers at the physical transfer of the products to the freight carriers. Transfer of title for shipments to Japanese customers occurs at the time of customer acceptance.
Management evaluates the need to record adjustments for impairment of inventory at least quarterly. The Company’s policy is to assess the valuation of all inventories including manufacturing raw materials, work-in-process, finished goods, and spare parts in each reporting period. Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated market value if less than cost. Estimates of market value include but are not limited to management’s forecasts related to the Company’s future manufacturing schedules, customer demand, technological and/or market obsolescence, general semiconductor market conditions, and possible alternative uses. If future customer demand or market conditions are less favorable than the Company’s projections, additional inventory write-downs may be required and would be reflected in cost of goods sold in the period in which the revision is made.
Warranty: Typically, the sale of semiconductor capital equipment includes providing parts and service warranties to customers as part of the overall price of the system. The Company provides standard warranties for its systems. The Company records a provision for estimated warranty expenses to cost of sales for each system when it recognizes revenue. The Company does not maintain general or unspecified reserves; all warranty reserves are related to specific systems. All actual or estimated parts and labor costs incurred in subsequent periods are charged to those established reserves on a system-by-system basis.
While the Company periodically monitors the performance and cost of warranty activities, if actual costs incurred are different than its estimates, the Company may recognize adjustments to provisions in the period in which those differences arise or are identified. In addition to the provision of standard warranties, the Company offers customer-paid extended warranty services. Revenues for extended maintenance and warranty services with a fixed payment amount are recognized on a straight-line basis over the term of the contract. Related costs are recorded as incurred.
Equity-based Compensation — Employee Stock Plans: The Company recognizes the fair value of equity-based compensation expense. The Company determines the fair value of its RSUs, excluding market-based performance RSUs, based upon the fair market value of Company’s Common Stock at the date of grant, discounted for dividends. The Company estimates the fair value of its market-based performance RSUs using a Monte Carlo simulation model at the date of the grant. The Company estimates the fair value of its stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions, including expected stock price volatility and the estimated life of each award. The Company amortizes the fair value of equity-based awards over the vesting periods of the award, and the Company has elected to use the straight-line method of amortization.
Income Taxes: Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, as well as the tax effect of carryforwards. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Realization of its net deferred tax assets is dependent on future taxable income. The Company believes it is more likely than not that such assets will be realized; however, ultimate realization could be negatively impacted by market conditions and other variables not known or anticipated at this time. In the event that the Company determines that it will not be able to realize all or part of its net deferred tax assets, an adjustment will be charged to earnings in the period such determination is made. Likewise, if the Company later determines that it is more likely than not that the deferred tax assets will be realized, then the previously provided valuation allowance will be reversed.
The Company recognizes the benefit from a tax position only if it is more likely than not that the position will be sustained upon audit based solely on the technical merits of the tax position. The Company’s policy is to include interest and penalties related to uncertain tax positions as a component of income tax expense.
Goodwill and Intangible Assets: The valuation of intangible assets acquired in a business combination requires the use of management estimates including but not limited to estimating future expected cash flows from assets acquired and determining discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates. Estimates associated with the accounting for acquisitions may change as additional information becomes available. The Company amortizes intangible assets with estimable useful lives over their respective estimated useful lives.
Goodwill represents the amount by which the purchase price in each business combination exceeds the fair value of the net tangible and identifiable intangible assets acquired. Each component of the Company for which discrete financial information is available and for which management regularly reviews the results of operations is considered a reporting unit. All goodwill acquired in a business combination is assigned to one or more reporting units as of the acquisition date. Goodwill is assigned to the Company’s reporting units that are expected to benefit from the synergies of the combination. The goodwill assigned to a reporting unit is the difference between the acquisition consideration assigned to the reporting unit on a relative fair value basis and the fair value of acquired assets and liabilities that can be specifically attributed to the reporting unit.
Lam Research Corporation 2022 10-K 46
The Company reviews goodwill at least annually for impairment during the fourth quarter of each fiscal year and if certain events or indicators of impairment occur between annual impairment tests. The process of evaluating the potential impairment of goodwill requires significant judgment. When reviewing goodwill for impairment, the Company first performs a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. In performing a qualitative assessment, it considers business conditions and other factors including, but not limited to (i) adverse industry or economic trends, (ii) restructuring actions and lower projections that may impact future operating results, (iii) sustained decline in share price, and (iv) overall financial performance and other events affecting the reporting units. If the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then a quantitative impairment test is performed by estimating the fair value of the reporting unit and comparing it to its carrying value, including goodwill allocated to that reporting unit. The Company did not record impairments of goodwill during the years ended June 26, 2022, June 27, 2021, or June 28, 2020.
The Company determines the fair value of its reporting units by using an income approach. Under the income approach, the Company determines fair value based on estimated future cash flows of each reporting unit, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn.
In estimating the fair value of a reporting unit, the Company makes estimates and judgments about the future cash flows of its reporting units, including estimated growth rates and assumptions about the economic environment. Although the Company’s cash flow forecasts are based on assumptions that are consistent with the plans and estimates it is using to manage the underlying businesses, there is significant judgment involved in determining the cash flows attributable to a reporting unit. In addition, the Company makes certain judgments about allocating shared assets to the estimated balance sheets of its reporting units. Changes in judgment on these assumptions and estimates could result in a goodwill impairment charge.
If after completing the quantitative assessment the carrying value of a reporting unit exceeds its fair value, the Company would record an impairment charge equal to the excess of the carrying value of the reporting unit over its fair value, up to the amount the goodwill assigned to the reporting unit.
Impairment of Long-lived Assets (Excluding Goodwill): The Company reviews intangible assets whenever events or circumstances indicate that the carrying value of an asset or asset group may not be recoverable. If such indicators are present, the Company determines whether the sum of the estimated undiscounted cash flows attributable to the assets is less than their carrying value. If the sum is less, the Company recognizes an impairment loss based on the excess of the carrying amount of the assets over their respective fair values. Fair value is determined by discounted future cash flows, appraisals, or other methods. The Company recognizes an impairment charge to the extent the fair value attributable to the asset are less than the asset’s carrying value. The fair value of the asset then becomes the asset’s new carrying value, which the Company depreciates over the remaining estimated useful life of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value. For the periods presented, there was no impairment of long-lived assets. In addition, for fully amortized intangible assets, we derecognize the gross cost and accumulated amortization in the period we determine the intangible asset no longer enhances future cash flows.
Fiscal Year: The Company follows a 52/53-week fiscal reporting calendar, and its fiscal year ends on the last Sunday of June each year. The Company’s most recent fiscal years ended June 26, 2022, June 27, 2021, and June 28, 2020, and each included 52 weeks.
Principles of Consolidation: The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Cash Equivalents and Investments: Investments purchased with an original maturity of three months or less are considered cash equivalents. The Company also invests in certain mutual funds, which include equity and fixed-income securities, related to its obligations under its deferred compensation plan, and such investments are classified as trading securities on the consolidated balance sheets. All of the Company’s other investments are classified as available-for-sale at the respective balance sheet dates. The Company accounts for its investment portfolio at fair value. Investments classified as trading securities are recorded at fair value based upon quoted market prices. Differences between the cost and fair value of trading securities are recognized as other income (expense), net in the Consolidated Statement of Operations. The investments classified as available-for-sale are recorded at fair value based upon quoted market prices, and difference between the cost and fair value of available-for-sale securities is presented as a component of accumulated other comprehensive income (loss). Following the fiscal year 2021 adoption of Accounting Standard Codification Topic 326, under Subtopic 326-30, the Company evaluates its investments with fair value less than amortized cost by first considering whether the Company has the intent to sell the security or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. In either such situation, the difference between fair value and amortized cost is recognized as a loss in the income statement. Where such sales are not likely to occur, the Company considers whether a portion of the loss is the result of a credit loss. To the extent such losses are the result of credit losses, those amounts are recognized in the income statement. All other differences between fair value and amortized cost are recognized in other comprehensive income. No such losses were recognized through the income statement during the years ended June 26, 2022 and June 27, 2021. No other-than-temporary impairment charges were recognized during the year ended June 28, 2020.
Lam Research Corporation 2022 10-K 47
Allowance for Expected Credit Losses: The Company maintains an allowance for expected losses resulting from the inability of its customers to make required payments. The Company evaluates its allowance for expected credit losses based on a combination of factors. In circumstances where specific invoices are deemed uncollectible, the Company provides a specific allowance against the amount due to reduce the net recognized receivable to the amount it reasonably believes will be collected. The Company also provides allowances based on its write-off history. Bad debt expense was not material for fiscal years ended June 26, 2022, June 27, 2021, and June 28, 2020.
Property and Equipment: Property and equipment is stated at cost. Equipment is depreciated by the straight-line method over the estimated useful lives of the assets, generally three to five years. Furniture and fixtures are depreciated by the straight-line method over the estimated useful lives of the assets, generally five years. Software is amortized by the straight-line method over the estimated useful lives of the assets, generally three to five years. Buildings are depreciated by the straight-line method over the estimated useful lives of the assets, generally twenty-five years. Leasehold improvements are generally amortized by the straight-line method over the shorter of the life of the related asset or the term of the underlying lease. Amortization of finance leases is included with depreciation expense.
Derivative Financial Instruments: In the normal course of business, the Company’s financial position is routinely subjected to market risk associated with interest rate and foreign currency exchange rate fluctuations. The Company’s policy is to mitigate the effect of interest rate fluctuations on certain proposed debt instruments and exchange rate fluctuations on certain foreign currency denominated business exposures. The Company has a policy that allows the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on forecasted revenue and expenses and net monetary assets or liabilities denominated in various foreign currencies. The Company carries derivative financial instruments (derivatives) on the balance sheet at their fair values. The Company does not use derivatives for trading or speculative purposes. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its interest rate and foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. The Company maintains an active currency hedging program and believes there is minimal risk that appropriate derivatives to maintain the Company’s hedging program would not be available in the future.
To hedge foreign currency risks, the Company uses foreign currency exchange forward and option contracts, where possible and prudent. These hedge contracts are valued using standard valuation formulas with assumptions about future foreign currency exchange rates derived from existing exchange rates, interest rates, and other market factors.
The Company considers its most current forecast in determining the level of foreign currency denominated revenue and expenses to hedge as cash flow hedges. The Company combines these forecasts with historical trends to establish the portion of its expected volume to be hedged. The revenue and expenses are hedged and designated as cash flow hedges to protect the Company from exposures to fluctuations in foreign currency exchange rates. If the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, the related hedge gains and losses on the cash flow hedge are reclassified from accumulated other comprehensive income (loss) to other income (expense), net on the Consolidated Statement of Operations at that time.
Leases: Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company includes renewals and terminations in the calculation of the right-of-use asset and liability when the provision is reasonably certain to be exercised. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future lease payments when the rate implicit in the lease is unknown.
The Company has elected the following practical expedients and accounting policy elections for accounting under ASC 842: (i) leases with an initial lease term of 12 months or less are not recorded on the balance sheet; and (ii) lease and non-lease components of a contract are accounted for as a single lease component.
Guarantees: The Company has certain finance leases that contain provisions whereby the properties subject to the finance leases may be remarketed at lease expiration. The Company has guaranteed to the lessor an amount approximating the lessor’s investment in the property. Also, the Company’s guarantees generally include certain indemnifications to its lessors for environmental matters, potential overdraft protection obligations to financial institutions related to one of the Company’s subsidiaries, indemnifications to the Company’s customers for certain infringement of third-party intellectual property rights by its products and services, indemnifications for its officers and directors, and the Company’s warranty obligations under sales of its products.
Foreign Currency Translation: The Company’s non-U.S. subsidiaries that operate in a local currency environment, where that local currency is the functional currency, primarily generate and expend cash in their local currency. Accordingly, all balance sheet accounts of these local functional currency subsidiaries are translated into U.S. dollars at the fiscal period-end exchange rate, and income and expense accounts are translated into U.S. dollars using average rates in effect for the period, except for costs related to those balance sheet items that are translated using historical exchange rates. The resulting translation adjustments are recorded as cumulative translation adjustments and are a component of accumulated other comprehensive income (loss). Remeasurement adjustments are recorded in other income (expense), net, where the U.S. dollar is the functional currency.
Lam Research Corporation 2022 10-K 48
Note 3: Recent Accounting Pronouncements
Recently Adopted or Effective
The Company did not adopt any new accounting standards during fiscal year 2022 that had a material impact on the Company’s Consolidated Financial Statements.
Updates Not Yet Effective
In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,” which requires business entities to make annual disclosures, including the nature of transactions and the related accounting policy used to account for the transactions, significant terms and conditions, and line items affected, about transactions with a government (including government assistance) that are accounted for by analogizing to a grant or contribution accounting model. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021, with early adoption permitted. The Company is required to adopt this standard in the first quarter of fiscal year 2023 for the annual reporting period ending June 25, 2023. The guidance may be applied either prospectively to all in-scope transactions at the date of initial application or retrospectively. The Company does not expect adoption of this standard to have a material impact on its Consolidated Financial Statements.
In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions,” which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair values; it also requires additional disclosures, including the nature and remaining duration of such restrictions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2023, with early adoption permitted. The Company is required to adopt this standard prospectively in the first quarter of fiscal year 2025 for the annual reporting period ending June 29, 2025. The Company does not expect adoption of this standard to have a material impact on its Consolidated Financial Statements.
Note 4: Revenue
Deferred Revenue
Revenue of $908.7 million included in deferred profit at June 27, 2021 was recognized during fiscal year 2022.
The following table summarizes the transaction price for contracts that have not yet been recognized as revenue as of June 26, 2022 and when the Company expects to recognize the amounts as revenue:
| | | | | | | | | | | | | | | | | | | | | | | |
| Less than 1 Year | | 1-3 Years | | More than 3 Years | | Total |
| (in thousands) |
| Deferred revenue | $ | 2,014,210 | | | $ | 160,266 | | (1) | $ | 23,623 | | (1) | $ | 2,198,099 | |
| | | | | | | |
(1) This amount is reported in Deferred profit on the Company's Consolidated Balance Sheets as the customers can demand the liability to be performed at any time.
Disaggregation of Revenue
The following table presents the Company’s revenue disaggregated between system and its customer-support related revenue:
| | | | | | | | | | | | | | | | | |
| Year Ended |
| June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| (in thousands) |
| Systems Revenue | $ | 11,322,271 | | | $ | 9,764,845 | | | $ | 6,625,130 | |
| Customer support-related revenue and other | 5,904,768 | | | 4,861,305 | | | 3,419,606 | |
| $ | 17,227,039 | | | $ | 14,626,150 | | | $ | 10,044,736 | |
| | | | | |
System revenue includes sales of new leading-edge equipment in deposition, etch and clean markets.
Customer support-related revenue includes sales of customer service, spares, upgrades, and non-leading-edge equipment from the Company’s Reliant product line.
Lam Research Corporation 2022 10-K 49
regarding the Company’s evaluation of reportable business segments and the disaggregation of revenue by the geographic regions in which the Company operates.
Additionally, the Company serves three primary markets: memory, foundry, and logic/integrated device manufacturing. The following table presents the percentages of leading- and non-leading-edge equipment and upgrade revenue to each of the primary markets the Company serves:
| | | | | | | | | | | | | | | | | |
| Year Ended |
| June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| Memory | 60 | % | | 61 | % | | 58 | % |
| Foundry | 26 | % | | 32 | % | | 31 | % |
| Logic/integrated device manufacturing | 14 | % | | 7 | % | | 11 | % |
Note 5: Equity-based Compensation Plan
The Company has stock plans that provide for grants of equity-based awards to eligible participants, including stock options and restricted stock units, of the Company’s Common Stock. An option is a right to purchase Common Stock at a set price. An RSU award is an agreement to issue a set number of shares of Common Stock at the time of vesting. The Company also has an employee stock purchase plan that allows employees to purchase its Common Stock at a discount through payroll deductions.
The Lam Research Corporation 2015 Stock Incentive Plan (the “Plan”) was approved by the stockholders and provides for the grant of non-qualified equity-based awards to eligible employees, consultants, advisors, and non-employee directors of the Company and its subsidiaries. As of the date of stockholder approval 19,232,068 authorized shares were available for issuance under the Plan; as of June 26, 2022, 8,038,265 shares remain available for future issuance to satisfy stock option exercises and vesting of awards.
The Company recognized the following equity-based compensation expense and benefits in the Consolidated Statements of Operations:
| | | | | | | | | | | | | | | | | |
| | Year Ended |
June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| | (in thousands) |
| Equity-based compensation expense | $ | 259,064 | | | $ | 220,164 | | | $ | 189,197 | |
| Income tax benefit recognized related to equity-based compensation | $ | 37,466 | | | $ | 49,313 | | | $ | 36,135 | |
| Income tax benefit realized from the exercise and vesting of options and RSUs | $ | 72,564 | | | $ | 97,275 | | | $ | 67,060 | |
| | | | | |
The estimated fair value of the Company’s equity-based awards, less expected forfeitures, is amortized over the awards’ vesting terms on a straight-line basis.
Restricted Stock Units
During the fiscal years 2022, 2021, and 2020, the Company issued both service-based RSUs and market-based performance RSUs (“PRSUs”). Service-based RSUs typically vest over a period of 3 years or less. Market-based PRSUs generally vest three years from the grant date if certain performance criteria are achieved and require continued employment. Based upon the terms of such awards, the number of shares that can be earned over the performance periods is based on the Company’s Common Stock price performance compared to the market price performance of a designated benchmark index, ranging from 0% to 150% of target. The designated benchmark index was the Philadelphia Semiconductor Total Return Index (“XSOX”). The stock price performance or market price performance is measured using the closing price for the 50-trading days prior to the dates the performance period begins and ends. The target number of shares represented by the market-based PRSUs is increased by 2% of target for each 1% that Common Stock price performance exceeds the market price performance of the designated benchmark index. Market-based PRSUs utilize the XSOX, which index gives effect to the reinvestment of dividends paid on its constituent holdings, as the benchmark; and accordingly, the Company's Common Stock price performance was adjusted for the reinvestment of dividends on Common Stock on the ex-dividend date. The result of the vesting formula is rounded down to the nearest whole number. Total stockholder return is a measure of stock price appreciation in this performance period.
Lam Research Corporation 2022 10-K 50
The following table summarizes the Company’s combined service-based RSUs and market-based PRSUs:
| | | | | | | | | | | |
| Number of
Shares
(in thousands) | | Weighted-Average
Grant Date Fair Value |
| Outstanding, June 27, 2021 | 1,306 | | | $ | 345.70 | |
| Granted | 606 | | | 518.45 | |
| Vested | (747) | | | 261.38 | |
| Forfeited or canceled | (64) | | | 404.08 | |
| Outstanding, June 26, 2022 | 1,101 | | | $ | 475.33 | |
| | | |
Of the 1.1 million shares outstanding at June 26, 2022, 904.0 thousand are service-based RSUs and 196.6 thousand are market-based PRSUs. The fair value of the Company’s service-based RSUs was calculated based on the fair market value of the Company’s stock at the date of grant, discounted for dividends. The fair value of the Company’s market-based PRSUs granted during fiscal years 2022, 2021, and 2020 was calculated using a Monte Carlo simulation model at the date of the grant, resulting in a weighted average grant-date fair value per share of $488.68, $640.69, and $320.69, respectively. The total fair value of service-based RSUs and market-based RSUs that vested during fiscal years 2022, 2021, and 2020 was $195.1 million, $177.4 million, and $166.9 million, respectively.
As of June 26, 2022, the Company had $418.8 million of total unrecognized compensation expense which is expected to be recognized over a weighted-average remaining period of approximately 2.2 years.
Stock Options
The Company granted stock options with a 7-year maximum contractual term to a limited group of executive officers during fiscal years 2022, 2021, and 2020. Stock options typically vest over a period of three years or less. The Company had 207.0 thousand options outstanding at June 26, 2022 with a weighted-average exercise price of $269.50 per share, of which 143.8 thousand were exercisable with a weighted-average exercise price of $189.59 per share. As of June 26, 2022, the Company had $7.8 million of total unrecognized compensation expense related to unvested stock options granted and outstanding which is expected to be recognized over a weighted-average remaining period of 2.3 years.
ESPP
The Company has an employee stock purchase plan (the “ESPP”) which allows employees to designate a portion of their base compensation to be deducted and used to purchase the Company’s Common Stock at a purchase price per share of the lower of 85% of the fair market value of the Company’s Common Stock on the first or last day of the applicable purchase period. Typically, each offering period lasts 12 months and contains one interim purchase date.
During fiscal year 2022, approximately 253 thousand shares of the Company’s Common Stock were sold to employees under the ESPP. At June 26, 2022, approximately 5.7 million shares were available for purchase, and the Company had $32.3 million of total unrecognized compensation cost, which is expected to be recognized over a remaining period of less than one year.
Note 6: Other Income (Expense), Net
The significant components of other income (expense), net, were as follows:
| | | | | | | | | | | | | | | | | |
| | Year Ended |
June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| (in thousands) |
| Interest income | $ | 15,209 | | | $ | 19,687 | | | $ | 85,433 | |
| Interest expense | (184,759) | | | (208,597) | | | (177,440) | |
| (Losses) gains on deferred compensation plan related assets, net | (38,053) | | | 61,838 | | | 5,999 | |
| | | | | |
| | | | | |
| Foreign exchange (losses) gains, net | (723) | | | (6,962) | | | (3,317) | |
| Other, net | 19,618 | | | 22,815 | | | (9,499) | |
| $ | (188,708) | | | $ | (111,219) | | | $ | (98,824) | |
| | | | | |
Interest income in the year ended June 26, 2022, decreased compared to the year ended June 27, 2021, primarily as a result of lower cash balances. Interest income decreased in the year ended June 27, 2021, compared to the year ended June 28, 2020, as a result of lower yield.
Lam Research Corporation 2022 10-K 51
Interest expense in the year ended June 26, 2022, decreased compared to the year ended June 27, 2021, primarily due to the payoff of $800 million of senior notes in June 2021. The increase in interest expense in the year ended June 27, 2021, compared to the year ended June 28, 2020, primarily due to the full year impact of the issuance of the $2.0 billion senior notes in fiscal year 2020.
The gains or losses on deferred compensation plan related assets, net in fiscal years 2022, 2021 and 2020 were driven by fluctuations in the fair market value of the underlying funds.
The variation in other, net for the year ended June 26, 2022 compared to the years ended June 27, 2021 and June 28, 2020 were primarily driven by fluctuations in the fair market value of equity investments.
Note 7: Income Taxes
The components of income before income taxes were as follows:
| | | | | | | | | | | | | | | | | |
| Year Ended |
| June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| | (in thousands) |
| United States | $ | 87,933 | | | $ | 120,161 | | | $ | 44,739 | |
| Foreign | 5,105,181 | | | 4,250,643 | | | 2,530,239 | |
| $ | 5,193,114 | | | $ | 4,370,804 | | | $ | 2,574,978 | |
| | | | | |
Significant components of the provision (benefit) for income taxes attributable to income before income taxes were as follows:
| | | | | | | | | | | | | | | | | |
| Year Ended |
| June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| | (in thousands) |
| Federal: | | | | | |
| Current | $ | 620,344 | | | $ | 437,525 | | | $ | 216,513 | |
| Deferred | (226,895) | | | (139,531) | | | (18,458) | |
| 393,449 | | | 297,994 | | | 198,055 | |
| State: | | | | | |
| Current | 20,759 | | | 13,560 | | | 4,724 | |
| Deferred | (19,096) | | | (8,324) | | | 6,524 | |
| 1,663 | | | 5,236 | | | 11,248 | |
| Foreign: | | | | | |
| Current | 204,163 | | | 162,738 | | | 119,766 | |
| Deferred | (11,447) | | | (3,622) | | | (5,844) | |
| 192,716 | | | 159,116 | | | 113,922 | |
| Total provision for income taxes | $ | 587,828 | | | $ | 462,346 | | | $ | 323,225 | |
| | | | | |
Lam Research Corporation 2022 10-K 52
Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, as well as the tax effect of carryforwards. Significant components of the Company’s net deferred tax assets and liabilities were as follows:
| | | | | | | | | | | |
| June 26,
2022 | | June 27,
2021 |
| | (in thousands) |
| Deferred tax assets: | | | |
| Tax carryforwards | $ | 315,396 | | | $ | 281,022 | |
| Allowances and reserves | 194,410 | | | 165,335 | |
| Equity-based compensation | 8,845 | | | 7,322 | |
| Inventory valuation differences | 52,323 | | | 28,877 | |
| | | |
| Outside basis differences of foreign subsidiaries | 421,056 | | | 193,734 | |
| Operating lease liabilities | 50,294 | | | 37,562 | |
| Finance lease assets | 35,754 | | | 35,600 | |
| Intangible assets | 889 | | | — | |
| Other | 23,955 | | | 22,575 | |
| Gross deferred tax assets | 1,102,922 | | | 772,027 | |
| Valuation allowance | (308,724) | | | (277,133) | |
| Net deferred tax assets | 794,198 | | | 494,894 | |
| Deferred tax liabilities: | | | |
| Intangible assets | — | | | (3,113) | |
| Capital assets | (114,644) | | | (81,412) | |
| Amortization of goodwill | (13,789) | | | (13,161) | |
| | | |
| Right-of-use assets | (50,294) | | | (37,562) | |
| Finance lease liabilities | (52,379) | | | (50,683) | |
| Other | (2,395) | | | (1,369) | |
| Gross deferred tax liabilities | (233,501) | | | (187,300) | |
| Net deferred tax assets | $ | 560,697 | | | $ | 307,594 | |
| | | |
The change in gross deferred tax assets, gross deferred tax liabilities, and valuation allowance between fiscal year 2022 and 2021 is primarily due to increases in gross deferred tax assets for outside basis differences of foreign subsidiaries and tax credits, and increases in gross deferred tax liabilities for capital assets.
The Company previously made an accounting policy election to record deferred taxes related to Global Intangible Low-Taxed Income (“GILTI”).
Realization of the Company’s net deferred tax assets is based upon the weighting of available evidence, including such factors as the recent earnings history and expected future taxable income. The Company believes it is more likely than not that such deferred tax assets will be realized with the exception of $308.7 million related to California deferred tax assets. At June 26, 2022, the Company continued to record a valuation allowance to offset the entire California deferred tax asset balance due to the single sales factor apportionment resulting in lower taxable income in California.
At June 26, 2022, the Company had federal net operating loss carryforwards of $16.0 million. If not utilized, these losses will begin to expire in fiscal year 2023, and are subject to limitation on their utilization.
At June 26, 2022, the Company had state net operating loss carryforwards of $144.7 million. If not utilized, these losses will begin to expire in fiscal year 2023 and are subject to limitation on their utilization.
At June 26, 2022, the Company had state tax credit carryforwards of $467.5 million. Substantially all of these credits can be carried forward indefinitely.
Lam Research Corporation 2022 10-K 53
A reconciliation of income tax expense provided at the federal statutory rate (21% in fiscal years 2022, 2021, and 2020) to actual income tax expense is as follows:
| | | | | | | | | | | | | | | | | |
| Year Ended |
| June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| | (in thousands) |
| Income tax expense computed at federal statutory rate | $ | 1,096,692 | | | $ | 917,869 | | | $ | 540,745 | |
| State income taxes, net of federal tax benefit | (35,584) | | | (33,478) | | | (28,046) | |
| Foreign income taxed at different rates | (407,989) | | | (365,886) | | | (146,023) | |
| Settlements and reductions in uncertain tax positions | (51,227) | | | (13,613) | | | (12,854) | |
| Tax credits | (96,440) | | | (86,709) | | | (88,762) | |
| State valuation allowance, net of federal tax benefit | 43,502 | | | 39,477 | | | 30,923 | |
| Equity-based compensation | (13,168) | | | (45,764) | | | (23,248) | |
| Other permanent differences and miscellaneous items | 52,042 | | | 50,450 | | | 50,490 | |
| | | | | |
| $ | 587,828 | | | $ | 462,346 | | | $ | 323,225 | |
| | | | | |
Effective from fiscal year 2022, the Company has a 15-year tax incentive ruling in Malaysia for one of its foreign subsidiaries. The statutory tax rate in Malaysia is 24%. The tax incentive provides exemptions on foreign income earned and is contingent upon meeting certain conditions. The Company expects to apply for renewals upon expiration. The impact of the tax incentive decreased worldwide taxes by approximately $574.7 million for fiscal year 2022. The benefit of the tax incentive on diluted earnings per share was approximately $4.09 in fiscal year 2022.
Earnings of the Company’s foreign subsidiaries included in consolidated retained earnings that are indefinitely reinvested in foreign operations aggregated to approximately $894.8 million at June 26, 2022. If these earnings were remitted to the United States, they would be subject to foreign withholding taxes of approximately $137.0 million at the current statutory rates. The potential tax expense associated with these foreign withholding taxes would be offset by $109.6 million of foreign tax credits that would be generated in the United States upon remittance.
On August 16, 2022, the Inflation Reduction Act was signed into law. In general, the provisions of the IRA will be effective beginning with the Company’s fiscal year 2024, with certain exceptions. The IRA includes a new 15% corporate minimum tax. The Company is in the process of evaluating the potential impacts of the IRA. The impact on income taxes due to changes in legislation is required under the authoritative guidance of ASC 740, Income Taxes, to be recognized in the period in which the law is enacted. While the Company does not currently expect the IRA to have a material impact on our effective tax rate, our analysis is ongoing and incomplete, and it is possible that the IRA could have a material adverse effect on the Company’s tax liability. The Company will continue to monitor issuance of additional guidance.
The Company’s gross uncertain tax positions were $617.4 million, $566.8 million, and $476.7 million as of June 26, 2022, June 27, 2021, and June 28, 2020, respectively. During fiscal year 2022, gross uncertain tax positions increased by $50.6 million. The amount of uncertain tax positions that, if recognized, would impact the effective tax rate was $539.6 million, $504.4 million, and $423.8 million, as of June 26, 2022, June 27, 2021, and June 28, 2020, respectively.
Lam Research Corporation 2022 10-K 54
The aggregate changes in the balance of gross uncertain tax positions were as follows:
| | | | | |
| |
| (in thousands) |
| Balance as of June 30, 2019 | $ | 420,772 | |
| Settlements and effective settlements with tax authorities | (1,836) | |
| Lapse of statute of limitations | (8,026) | |
| Increases in balances related to tax positions taken during prior periods | 3,206 | |
| Decreases in balances related to tax positions taken during prior periods | (3,989) | |
| Increases in balances related to tax positions taken during current period | 66,568 | |
| Balance as of June 28, 2020 | 476,695 | |
| Settlements and effective settlements with tax authorities | (1,443) | |
| Lapse of statute of limitations | (8,456) | |
| Increases in balances related to tax positions taken during prior periods | 15,986 | |
| Decreases in balances related to tax positions taken during prior periods | (2,746) | |
| Increases in balances related to tax positions taken during current period | 86,735 | |
| Balance as of June 27, 2021 | 566,771 | |
| Settlements and effective settlements with tax authorities | (14,440) | |
| Lapse of statute of limitations | (8,021) | |
| Increases in balances related to tax positions taken during prior periods | 6,468 | |
| Decreases in balances related to tax positions taken during prior periods | (28,376) | |
| Increases in balances related to tax positions taken during current period | 94,971 | |
| Balance as of June 26, 2022 | $ | 617,373 | |
| |
The Company recognizes interest expense and penalties related to the above uncertain tax positions within income tax expense. The Company had accrued $61.2 million, $54.6 million, and $40.2 million cumulatively for gross interest and penalties as of June 26, 2022, June 27, 2021, and June 28, 2020, respectively.
The Company is subject to audits by state and foreign tax authorities. The Company is unable to make a reasonable estimate as to when cash settlements, if any, with the relevant taxing authorities will occur.
The Company files U.S. federal, U.S. state, and foreign income tax returns. As of June 26, 2022, tax years 2004-2022 remain subject to examination in the jurisdictions where the Company operates. The Internal Revenue Service (“IRS”) is examining the Company’s U.S. federal income tax return for the fiscal year ended June 24, 2018. As of June 26, 2022, the IRS has proposed adjustments resulting in a tax liability increase of approximately $50.0 million. If the Company agrees to the proposed adjustments, cash settlements with respect to the increased liabilities will be made accordingly.
The Company is in various stages of examinations in connection with all of its tax audits worldwide, and it is difficult to determine when these examinations will be settled. It is reasonably possible that over the next 12-month period the Company may experience an increase or decrease in its uncertain tax positions as a result of tax examinations or lapses of statutes of limitation. The change in uncertain tax positions may range up to $20.0 million.
Lam Research Corporation 2022 10-K 55
Note 8: Net Income per Share
Basic net income per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the treasury stock method, for dilutive stock options, restricted stock units, and convertible notes.
The following table reconciles the inputs to the basic and diluted computations for net income per share.
| | | | | | | | | | | | | | | | | | |
| | Year Ended | |
June 26,
2022 | | June 27,
2021 | | June 28,
2020 | |
| | (in thousands, except per share data) | |
| Numerator: | | | | | | |
| Net income | $ | 4,605,286 | | | $ | 3,908,458 | | | $ | 2,251,753 | | |
| Denominator: | | | | | | |
| Basic average shares outstanding | 139,899 | | | 143,609 | | | 144,814 | | |
| Effect of potential dilutive securities: | | | | | | |
| Employee stock plans | 729 | | | 1,168 | | | 1,236 | | |
| Convertible notes | — | | | 543 | | | 3,040 | | |
| | | | | | |
| Diluted average shares outstanding | 140,628 | | | 145,320 | | | 149,090 | | |
| Net income per share - basic | $ | 32.92 | | | $ | 27.22 | | | $ | 15.55 | | |
| Net income per share - diluted | $ | 32.75 | | | $ | 26.90 | | | $ | 15.10 | | |
| | | | | | |
For purposes of computing diluted net income per share, weighted-average common shares do not include potentially dilutive securities that are anti-dilutive under the treasury stock method. The impact from potentially dilutive securities, including options and RSUs, were not material for fiscal years ended June 26, 2022, June 27, 2021, and June 28, 2020.
Note 9: Financial Instruments
Fair Value
The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability.
A fair value hierarchy has been established that prioritizes the inputs to valuation techniques used to measure fair value. The level of an asset or liability in the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities with sufficient volume and frequency of transactions.
Level 2: Valuations based on observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are less active for identical assets or liabilities, or model-derived valuations techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3: Valuations based on unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities and based on non-binding, broker-provided price quotes and may not have been corroborated by observable market data.
The Company engages with pricing vendors to provide fair values for a majority of its Level 1 and Level 2 investments. The vendors provide either a quoted market price or use observable inputs without applying significant adjustments in their pricing. Significant observable inputs include interest rates and yield curves observable at commonly quoted intervals, volatility and credit risks. The fair value of derivative contracts is determined using observable market inputs such as the foreign currency rates, forward rate curves, currency volatility and interest rates and considers nonperformance risk of the Company and its counterparties.
The Company’s primary financial instruments include its cash, cash equivalents, investments, restricted cash and investments, long-term investments, accounts receivable, accounts payable, long-term debt and leases, and foreign currency related derivative instruments. The estimated fair value of cash, time deposits, accounts receivable, and accounts payable approximates their carrying value due to the short period of time to their maturities. The estimated fair values of lease obligations approximate their carrying value as the majority of these obligations have interest rates that adjust to market rates on a periodic basis. Refer to Note 14 - Long Term Debt and Other Borrowings for additional information regarding the fair value of the Company’s senior notes.
Lam Research Corporation 2022 10-K 56
Investments
Equity Investments measured at fair value on a non-recurring basis
As of June 26, 2022 and June 27, 2021, equity investments of $125.2 million and $117.3 million, respectively, were recognized in other assets in the Consolidated Balance Sheets.
Net gains resulting from the application of the measurement alternative to the Company’s equity investments were immaterial in the fiscal years ended 2022, 2021, and 2020. During the fiscal year 2022, one of the Company’s equity investees became publicly traded and the market value of that investee fluctuated throughout the fiscal year; the Company liquidated its position in this equity investee during the last quarter of the fiscal year ended June 26, 2022 and recognized an immaterial cumulative gain on disposition.
Debt and Equity Investments measured at fair value on a recurring basis
The following tables set forth the Company’s cash, cash equivalents, investments, restricted cash and investments, and other assets measured at fair value on a recurring basis as of June 26, 2022, and June 27, 2021:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | June 26, 2022 |
| | | | | | | | | (Reported Within) |
| Cost | | Unrealized
Gain | | Unrealized
(Loss) | | Fair Value | | Cash and
Cash
Equivalents | | Investments | | Restricted
Cash &
Investments | | Other
Assets |
| (in thousands) |
| Level 1: | | | | | | | | | | | | | | | |
| Money market funds | $ | 712,076 | | | $ | — | | | $ | — | | | $ | 712,076 | | | $ | 712,076 | | | $ | — | | | $ | — | | | $ | — | |
| | | | | | | | | | | | | | | |
| Mutual funds | 84,851 | | | 12,027 | | | (1,659) | | | 95,219 | | | — | | | — | | | — | | | 95,219 | |
| Level 1 total | 796,927 | | | 12,027 | | | (1,659) | | | 807,295 | | | 712,076 | | | — | | | — | | | 95,219 | |
| Level 2: | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Corporate notes and bonds | 137,859 | | | — | | | (2,128) | | | 135,731 | | | — | | | 135,731 | | | — | | | — | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Level 2 Total | 137,859 | | | — | | | (2,128) | | | 135,731 | | | — | | | 135,731 | | | — | | | — | |
Total subject to fair value hierarchy | $ | 934,786 | | | $ | 12,027 | | | $ | (3,787) | | | $ | 943,026 | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Cash | | | | | | | 1,017,253 | | | 1,015,747 | | | — | | | 1,506 | | | — | |
| Time deposits | | | | | | | 2,044,206 | | | 1,794,178 | | | — | | | 250,028 | | | — | |
| Total | | | | | | | $ | 4,004,485 | | | $ | 3,522,001 | | | $ | 135,731 | | | $ | 251,534 | | | $ | 95,219 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | June 27, 2021 |
| | | | | | | | | (Reported Within) |
| Cost | | Unrealized
Gain | | Unrealized
(Loss) | | Fair Value | | Cash and
Cash
Equivalents | | Investments | | Restricted
Cash &
Investments | | Other
Assets |
| | (in thousands) |
| Level 1: | | | | | | | | | | | | | | | |
| Money market funds | $ | 2,246,138 | | | $ | — | | | $ | — | | | $ | 2,246,138 | | | $ | 2,246,138 | | | $ | — | | | $ | — | | | $ | — | |
| U.S. Treasury and agencies | 204,743 | | | 96 | | | (47) | | | 204,792 | | | — | | | 204,792 | | | — | | | — | |
| Mutual funds | 80,694 | | | 15,510 | | | (33) | | | 96,171 | | | — | | | — | | | — | | | 96,171 | |
| Level 1 total | 2,531,575 | | | 15,606 | | | (80) | | | 2,547,101 | | | 2,246,138 | | | 204,792 | | | — | | | 96,171 | |
| Level 2: | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Government-sponsored enterprises | 3,498 | | | 7 | | | — | | | 3,505 | | | — | | | 3,505 | | | — | | | — | |
| Foreign government bonds | 32,995 | | | 21 | | | (4) | | | 33,012 | | | — | | | 33,012 | | | — | | | — | |
| Corporate notes and bonds | 1,043,308 | | | 2,247 | | | (457) | | | 1,045,098 | | | — | | | 1,045,098 | | | — | | | — | |
| Mortgage backed securities - residential | 5,623 | | | 54 | | | — | | | 5,677 | | | — | | | 5,677 | | | — | | | — | |
| Mortgage backed securities - commercial | 18,830 | | | 17 | | | (59) | | | 18,788 | | | — | | | 18,788 | | | — | | | — | |
| Level 2 Total | 1,104,254 | | | 2,346 | | | (520) | | | 1,106,080 | | | — | | | 1,106,080 | | | — | | | — | |
Total subject to fair value hierarchy | $ | 3,635,829 | | | $ | 17,952 | | | $ | (600) | | | $ | 3,653,181 | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Cash | | | | | | | 875,738 | | | 873,278 | | | — | | | 2,460 | | | — | |
| Time deposits | | | | | | | 1,548,874 | | | 1,298,847 | | | — | | | 250,027 | | | — | |
| Total | | | | | | | $ | 6,077,793 | | | $ | 4,418,263 | | | $ | 1,310,872 | | | $ | 252,487 | | | $ | 96,171 | |
| | | | | | | | | | | | | | | |
The Company accounts for its investment portfolio at fair value. Realized gains (losses) for investment sales are specifically identified. Management assesses the fair value of investments in debt securities that are not actively traded through consideration of interest rates and their impact on the present value of the cash flows to be received from the investments.
Lam Research Corporation 2022 10-K 57
The Company evaluates its investments with fair value less than amortized cost by first considering whether the Company has the intent to sell the security or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. In either such situation, the difference between fair value and amortized cost is recognized as a loss in the income statement. Where such sales are not likely to occur, the Company considers whether a portion of the loss is the result of a credit loss. To the extent such losses are the result of credit losses, those amounts are recognized in the income statement. All other differences between fair value and amortized cost are recognized in other comprehensive income. No such losses were recognized through the income statement during the twelve months ended June 26, 2022, and June 27, 2021.
Gross realized gains/(losses) from sales of investments were insignificant in the fiscal years 2022, 2021, and 2020.
The following is an analysis of the Company’s investments in unrealized loss positions.:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | June 26, 2022 |
Unrealized Losses
Less than 12 Months | | Unrealized Losses
12 Months or Greater | | Total |
| Fair Value | | Gross
Unrealized
Loss | | Fair Value | | Gross
Unrealized
Loss | | Fair Value | | Gross
Unrealized
Loss |
| | (in thousands) |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Mutual funds | $ | 38,536 | | | $ | (1,447) | | | $ | 1,701 | | | $ | (212) | | | $ | 40,237 | | | $ | (1,659) | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Corporate notes and bonds | 134,964 | | | (2,128) | | | — | | | — | | | 134,964 | | | (2,128) | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| $ | 173,500 | | | $ | (3,575) | | | $ | 1,701 | | | $ | (212) | | | $ | 175,201 | | | $ | (3,787) | |
| | | | | | | | | | | |
The amortized cost and fair value of cash equivalents, investments, and restricted investments with contractual maturities as of June 26, 2022, are as follows:
| | | | | | | | | | | |
| Cost | | Fair Value |
| | (in thousands) |
| Due in one year or less | $ | 2,829,420 | | | $ | 2,828,556 | |
| Due after one year through five years | 64,721 | | | 63,457 | |
| | | |
| $ | 2,894,141 | | | $ | 2,892,013 | |
| | | |
The Company has the ability, if necessary, to liquidate its investments in order to meet the Company’s liquidity needs in the next 12 months. Accordingly, those investments with contractual maturities greater than 12 months from the date of purchase nonetheless are classified as short-term on the accompanying Consolidated Balance Sheets.
Derivative Instruments and Hedging
The Company carries derivative financial instruments (“derivatives”) on its Consolidated Balance Sheets at their fair values. The Company enters into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective of reducing volatility of earnings and cash flows related to foreign currency exchange rate fluctuations. In addition, the Company enters into interest rate swap arrangements to manage interest rate risk. The counterparties to these derivatives are large, global financial institutions that the Company believes are creditworthy, and therefore, it does not consider the risk of counterparty nonperformance to be material.
Under the master netting agreements with the respective counterparties to the Company’s derivative contracts, subject to applicable requirements, the Company is allowed to net settle transactions of the same currency with a single net amount payable by one party to the other. However, the Company has elected to present the derivative assets and derivative liabilities on a gross basis on its balance sheet. As of June 26, 2022 and June 27, 2021, the potential effect of rights of offset associated with the above foreign exchange and interest rate contracts would be immaterial to the Consolidated Balance Sheets.
Cash Flow Hedges
The Company’s financial position is routinely subjected to market risk associated with foreign currency exchange rate fluctuations on non-U.S. dollar transactions or cash flows. The Company’s policy is to mitigate the foreign exchange risk arising from the fluctuations in the value of these non-U.S. dollar denominated transactions or cash flows through a foreign currency cash flow hedging program, using forward contracts and foreign currency options that generally expire within 12 months and no later than 24 months. These hedge contracts are designated as cash flow hedges and are carried on the Company’s balance sheet at fair value with the effective portion of the contracts’ gains or losses included in accumulated other comprehensive income (loss) and subsequently recognized in revenue/expense in the same period the hedged items affect earnings.
In addition, the Company has entered into interest rate swap agreements to hedge against the variability of cash flows due to changes in certain benchmark interest rates on fixed rate debt. These instruments are designated as cash flow hedges at inception and are settled in conjunction with the issuance of debt. The effective portion of the contracts’ gains or losses is included in accumulated other comprehensive income (loss) and is amortized into income as the hedged item affects earnings. During the year
Lam Research Corporation 2022 10-K 58
ended June 28, 2020, the company recognized a net loss of $31.5 million of accumulated other comprehensive income, net of tax, related to interest rate swap agreements. No such activity occurred during the years ended June 26, 2022 or June 27, 2021.
At inception and at each quarter-end, hedges are tested prospectively and retrospectively for effectiveness using regression analysis. Changes in the fair value of foreign exchange contracts due to changes in time value are included in the assessment of effectiveness. To qualify for hedge accounting, the hedge relationship must meet criteria relating to both the derivative instrument and the hedged item. These criteria include identification of the hedging instrument, the hedged item, the nature of the risk being hedged, and how the hedging instrument’s effectiveness in offsetting the exposure to changes in the hedged item’s fair value or cash flows will be measured.
To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be tested to demonstrate an expectation of providing highly effective offsetting changes to future cash flows on hedged transactions. When derivative instruments are designated and qualify as effective cash flow hedges, the Company recognizes effective changes in the fair value of the hedging instrument within accumulated other comprehensive income (loss) until the hedged exposure is realized. Consequently, the Company’s results of operations are not subject to fluctuation as a result of changes in the fair value of the derivative instruments. If hedges are not highly effective or if the Company does not believe that the underlying hedged forecasted transactions will occur, the Company may not be able to account for its derivative instruments as cash flow hedges. If this were to occur, future changes in the fair values of the Company’s derivative instruments would be recognized in earnings. Additionally, related amounts previously recorded in other comprehensive income would be reclassified to earnings immediately. There were no material gains or losses during the fiscal years ended June 26, 2022, June 27, 2021, or June 28, 2020 associated with forecasted transactions that did not occur, nor any ineffectiveness recognized in the same periods.
As of June 26, 2022, the fair value of outstanding cash flow hedges was not material. Additionally, as of June 26, 2022, the Company had an immaterial net gain or loss accumulated in other comprehensive income, net of tax, related to foreign exchange cash flow hedges and interest rate contracts which it expects to reclassify from other comprehensive income into earnings over the next 12 months.
The following table provides the total notional value of cash flow hedge instruments outstanding as of June 26, 2022:
| | | | | |
| June 26, 2022 |
| (In thousands) |
| Buy Contracts | $ | 306,211 | |
| Sell Contracts | 541,999 | |
The effect of derivative instruments designated as cash flow hedges on the Company’s Consolidated Statements of Operations, including accumulated other comprehensive income (“AOCI”), was as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Year Ended June 26, 2022 | | Year Ended June 27, 2021 |
| | Location of
Gain (Loss)
Recognized in or
Reclassified into
Income | Gain
Recognized
in AOCI | | Gain (Loss)
Reclassified
from AOCI
into Income | | Gain (Loss)
Recognized
in AOCI | | Gain (Loss) Reclassified
from AOCI
into Income |
| |
| Derivatives in Cash Flow Hedging Relationships | (in thousands) |
| Foreign exchange contracts | Revenue | $ | 57,058 | | | $ | 45,057 | | | $ | 17,614 | | | $ | 868 | |
| Foreign exchange contracts | Cost of goods sold | (23,414) | | | (11,410) | | | 3,756 | | | 3,659 | |
| Foreign exchange contracts | R&D | (1,948) | | | (10) | | | 898 | | | — | |
| Foreign exchange contracts | SG&A | (6,914) | | | (2,434) | | | 4,190 | | | 3,623 | |
| | | | | | | | |
| Interest rate contracts | Other income (expense), net | — | | | (4,238) | | | — | | | (3,855) | |
| | $ | 24,782 | | | $ | 26,965 | | | $ | 26,458 | | | $ | 4,295 | |
| | | | | | | | |
Balance Sheet Hedges
The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily cash, third-party accounts receivable, accounts payable, and intercompany receivables and payables. These forward contracts are not designated for hedge accounting treatment. Therefore, the change in the carrying value of these derivatives is recorded as a component of other income (expense),net and offsets the change in fair value of the foreign currency denominated assets and liabilities related to remeasurement, which are also recorded in other income (expense), net. As of June 26, 2022 and June 27, 2021, the fair value of outstanding balance sheet hedges was not material.
Lam Research Corporation 2022 10-K 59
The following table provides the total notional value of balance sheet hedge instruments outstanding as of June 26, 2022:
| | | | | |
| June 26, 2022 |
| (In thousands) |
| Buy Contracts | $ | 184,310 | |
| Sell Contracts | 326,776 | |
The effect of the Company’s balance sheet hedge derivative instruments on the Company’s Consolidated Statements of Operations was as follows:
| | | | | | | | | | | | | | |
| | Year Ended |
| June 26, 2022 | | June 27, 2021 |
| Derivatives Not Designated as Hedging Instruments: | Location of Gain
Recognized
in Income | Gain
Recognized
in Income | | Gain
Recognized
in Income |
| | | (in thousands) |
| Foreign exchange contracts | Other income (expense), net | $ | 14,362 | | | $ | 7,057 | |
| | | | |
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, investments, restricted cash and investments, trade accounts receivable, and derivative financial instruments used in hedging activities. Cash is placed on deposit at large, global financial institutions. Such deposits may be in excess of insured limits. Management believes that the financial institutions that hold the Company’s cash are creditworthy and, accordingly, minimal credit risk exists with respect to these balances.
The Company’s overall portfolio of available-for-sale securities must maintain an average minimum rating of “AA-” or “Aa3” as rated by Standard and Poor’s, Fitch Ratings, or Moody’s Investor Services. To ensure diversification and minimize concentration, the Company’s policy limits the amount of credit exposure with any one financial institution or commercial issuer.
The Company is exposed to credit losses in the event of nonperformance by counterparties on foreign currency and interest rate hedge contracts that are used to mitigate the effect of exchange rate and interest rate fluctuations and on contracts related to structured share repurchase arrangements. These counterparties are large, global financial institutions and, to date, no such counterparty has failed to meet its financial obligations to the Company.
Credit risk evaluations, including trade references, bank references, and Dun & Bradstreet ratings, are performed on all new customers, and the Company monitors its customers’ financial condition and payment performance. In general, the Company does not require collateral on sales.
As of June 26, 2022, two customers accounted for approximately 20% and 14% of accounts receivable, respectively. As of June 27, 2021, two customers accounted for approximately 23%, and 13% of accounts receivable, respectively. No other customers accounted for more than 10% of accounts receivable, respectively. The Company’s balance and transactional activity for its allowance for doubtful accounts is not material as of and for the twelve months ended June 26, 2022, June 27, 2021, and June 28, 2020. Refer to Note 20 - Segment, Geographic Information, and Major Customers for additional information regarding customer concentrations. Note 10: Inventories
Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. System shipments to customers in Japan, for which title does not transfer until customer acceptance, are classified as finished goods inventory and carried at cost until title transfers. Inventories consist of the following:
| | | | | | | | | | | |
| June 26,
2022 | | June 27,
2021 |
| | (in thousands) |
| Raw materials | $ | 2,401,490 | | | $ | 1,519,456 | |
| Work-in-process | 471,348 | | | 391,686 | |
| Finished goods | 1,093,456 | | | 778,152 | |
| $ | 3,966,294 | | | $ | 2,689,294 | |
| | | |
Lam Research Corporation 2022 10-K 60
Note 11: Property and Equipment
Property and equipment, net, is presented in the table below.
| | | | | | | | | | | |
| June 26,
2022 | | June 27,
2021 |
| | (in thousands) |
| Manufacturing and engineering equipment | $ | 1,588,805 | | | $ | 1,328,399 | |
| Buildings and improvements | 1,124,381 | | | 840,661 | |
| Computer and computer-related equipment | 177,198 | | | 181,781 | |
| Office equipment, furniture and fixtures | 70,642 | | | 95,259 | |
| Land | 84,733 | | | 84,681 | |
| | | |
| 3,045,759 | | | 2,530,781 | |
| Less: accumulated depreciation and amortization | (1,440,325) | | | (1,271,356) | |
| $ | 1,605,434 | | | $ | 1,259,425 | |
| | | |
The Company has excluded $42.2 million, and $44.1 million of finance right-of-use assets recorded within property and equipment, net from the table above for the years ended June 26, 2022 and June 27, 2021, respectively. See Note 15 - Leases for additional information regarding these finance lease right-of-use assets. Depreciation expense, excluding amortization of finance lease right of use assets, during fiscal years 2022, 2021, and 2020 was $248.2 million, $229.8 million, and $198.8 million, respectively. Note 12: Goodwill and Intangible Assets
Goodwill
The balance of goodwill was $1.5 billion as of June 26, 2022 and June 27, 2021. As of June 26, 2022 and June 27, 2021, $62.0 million and $61.1 million, respectively, of the goodwill balance is tax deductible, and the remaining balance is not tax deductible due to purchase accounting and applicable foreign law. No goodwill impairments were recognized in fiscal years 2022, 2021, or 2020.
Intangible Assets
The following table provides details of the Company’s intangible assets, other than goodwill:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| June 26, 2022 | | June 27, 2021 |
| Gross | | Accumulated
Amortization | | Net | | Gross | | Accumulated
Amortization | | Net |
| | (in thousands) |
| Customer relationships | $ | 633,252 | | | $ | (627,376) | | | $ | 5,876 | | | $ | 630,303 | | | $ | (581,406) | | | $ | 48,897 | |
| Existing technology | 676,924 | | | (664,278) | | | 12,646 | | | 669,359 | | | (659,898) | | | 9,461 | |
| Patents and other intangible assets | 167,821 | | | (84,493) | | | 83,328 | | | 132,774 | | | (58,767) | | | 74,007 | |
| Total intangible assets | $ | 1,477,997 | | | $ | (1,376,147) | | | $ | 101,850 | | | $ | 1,432,436 | | | $ | (1,300,071) | | | $ | 132,365 | |
| | | | | | | | | | | |
The Company recognized $78.0 million, $70.6 million, and $66.2 million in intangible asset amortization expense during fiscal years 2022, 2021, and 2020, respectively. No intangible asset impairments were recognized in fiscal years 2022, 2021, or 2020.
The estimated future amortization expense of intangible assets as of June 26, 2022, is reflected in the table below. The table excludes $17.8 million of capitalized costs for intangible assets that have not yet been placed into service.
| | | | | |
| Fiscal Year | Amount |
| | (in thousands) |
| 2023 | $ | 36,726 | |
| 2024 | 22,983 | |
| 2025 | 12,882 | |
| 2026 | 5,707 | |
| 2027 | 3,343 | |
| Thereafter | 2,402 | |
| $ | 84,043 | |
| |
Lam Research Corporation 2022 10-K 61
Note 13: Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following:
| | | | | | | | | | | |
| June 26,
2022 | | June 27,
2021 |
| | (in thousands) |
| Accrued compensation | $ | 481,070 | | | $ | 552,925 | |
| Warranty reserves | 232,248 | | | 176,030 | |
| Income and other taxes payable | 465,601 | | | 348,206 | |
| Dividend payable | 205,615 | | | 185,431 | |
| Other | 589,738 | | | 456,891 | |
| $ | 1,974,272 | | | $ | 1,719,483 | |
| | | |
Note 14: Long Term Debt and Other Borrowings
As of June 26, 2022, and June 27, 2021, the Company’s outstanding debt consisted of the following:
| | | | | | | | | | | | | | | | | | | | | | | | |
| June 26, 2022 | | June 27, 2021 | |
| Amount
(in thousands) | | Effective Interest Rate | | Amount
(in thousands) | | Effective Interest Rate | |
Fixed-rate 3.80% Senior Notes Due March 15, 2025 (“2025 Notes”) | $ | 500,000 | | | 3.87 | % | | $ | 500,000 | | | 3.87 | % | |
Fixed-rate 3.75% Senior Notes Due March 15, 2026 ("2026 Notes") | 750,000 | | | 3.86 | % | | 750,000 | | | 3.86 | % | |
Fixed-rate 4.00% Senior Notes Due March 15, 2029 ("2029 Notes") | 1,000,000 | | | 4.09 | % | | 1,000,000 | | | 4.09 | % | |
Fixed-rate 1.90% Senior Note Due June 15, 2030 ("2030 Notes") | 750,000 | | | 2.01 | % | | 750,000 | | | 2.01 | % | |
Fixed-rate 4.875% Senior Notes Due March 15, 2049 ("2049 Notes") | 750,000 | | | 4.93 | % | | 750,000 | | | 4.93 | % | |
Fixed-rate 2.875% Senior Note Due June 15, 2050 ("2050 Notes") | 750,000 | | | 2.93 | % | | 750,000 | | | 2.93 | % | |
Fixed-rate 3.125% Senior Note Due June 15, 2060 ("2060 Notes") | 500,000 | | | 3.18 | % | | 500,000 | | | 3.18 | % | |
| Total debt outstanding, at par | 5,000,000 | | | | | 5,000,000 | | | | |
| Unamortized discount | (35,549) | | | | | (38,243) | | | | |
| Fair value adjustment - interest rate contracts | 4,835 | | (1) | | | 6,621 | | (1) | | |
| Unamortized bond issuance costs | (6,827) | | | | | (7,443) | | | | |
| Total debt outstanding, at carrying value | $ | 4,962,459 | | | | | $ | 4,960,935 | | | | |
| Reported as: | | | | | | | | |
| | | | | | | | |
| Long-term debt | $ | 4,962,459 | | | | | $ | 4,960,935 | | | | |
| | | | | | | | |
| | | | | | | | |
(1)This amount represents a cumulative fair value gain for discontinued hedging relationships, net of an immaterial amount of amortization as of the periods presented.
The Company’s contractual cash obligations relating to its outstanding debt as of June 26, 2022, were as follows:
| | | | | | | | | | | |
| Payments Due by Fiscal Year: | Principal | | Interest |
| | (in thousands) |
| 2023 | $ | — | | | $ | 175,125 | |
| 2024 | — | | | 175,125 | |
| 2025 | 500,000 | | | 175,125 | |
| 2026 | 750,000 | | | 161,222 | |
| 2027 | — | | | 128,000 | |
| Thereafter | 3,750,000 | | | 1,914,214 | |
| Total | $ | 5,000,000 | | | $ | 2,728,811 | |
| | | |
Senior Notes
On May 5, 2020, the Company completed a public offering of $750 million aggregate principal amount of the Company’s Senior Notes due June 15, 2030 (the “2030 Notes”), $750 million aggregate principal amount of the Company’s Senior Notes due June 15, 2050 (the “2050 Notes”), and $500 million aggregate principal amount of the Company’s Senior Notes due June 15, 2060 (the “2060 Notes”). The Company pays interest at an annual rate of 1.90%, 2.875%, and 3.125%, on the 2030, 2050, and 2060 Notes, respectively, on a semi-annual basis on June 15 and December 15 of each year.
On March 4, 2019, the Company completed a public offering of $750 million aggregate principal amount of the Company’s Senior Notes due March 15, 2026 (the “2026 Notes”), $1.0 billion aggregate principal amount of the Company’s Senior Notes due March 15,
Lam Research Corporation 2022 10-K 62
2029 (the “2029 Notes”), and $750 million aggregate principal amount of the Company’s Senior Notes due March 15, 2049 (the “2049 Notes”). The Company pays interest at an annual rate of 3.75%, 4.00%, and 4.875%, on the 2026, 2029, and 2049 Notes, respectively, on a semi-annual basis on March 15 and September 15 of each year.
On March 12, 2015, the Company completed a public offering of $500 million aggregate principal amount of the Company’s Senior Notes due March 15, 2025 (the “2025 Notes”). The Company pays interest at an annual rate of 3.80% on the 2025 Notes on a semi-annual basis on March 15 and September 15 of each year.
The Company may redeem the 2025, 2026, 2029, 2030, 2049, 2050, and 2060 Notes (collectively the “Senior Notes”) at a redemption price equal to 100% of the principal amount of such series (“par”), plus a “make whole” premium as described in the indenture in respect to the Senior Notes and accrued and unpaid interest before December 15, 2024 for the 2025 Notes, before January 15, 2026 for the 2026 Notes, before December 15, 2028 for the 2029 Notes, before March 15, 2030 for the 2030 Notes, before September 15, 2048 for the 2049 Notes, before December 15, 2049 for the 2050 Notes, and before December 15, 2059 for the 2060 Notes. The Company may redeem the Senior Notes at par, plus accrued and unpaid interest at any time on or after December 24, 2024 for the 2025 Notes, on or after January 15, 2026 for the 2026 Notes, on or after December 15, 2028 for the 2029 Notes, on or after March 15, 2030 for the 2030 Notes, on or after September 15, 2048 for the 2049 Notes, on or after December 15, 2049 for the 2050 Notes, and on or after December 15, 2059 for the 2060 Notes. In addition, upon the occurrence of certain events, as described in the indenture, the Company will be required to make an offer to repurchase the Senior Notes at a price equal to 101% of the principal amount of the respective note, plus accrued and unpaid interest.
Selected additional information regarding the Senior Notes outstanding as of June 26, 2022, is as follows:
| | | | | | | | | | | |
| Remaining Amortization period | | Fair Value of Notes (Level 2) |
| (years) | | (in thousands) |
| | | |
| 2025 Notes | 2.7 | | $ | 498,500 | |
| 2026 Notes | 3.7 | | $ | 745,103 | |
| 2029 Notes | 6.7 | | $ | 980,970 | |
| 2030 Notes | 8.0 | | $ | 632,693 | |
| 2049 Notes | 26.7 | | $ | 764,078 | |
| 2050 Notes | 28.0 | | $ | 546,735 | |
| 2060 Notes | 38.0 | | $ | 360,625 | |
Revolving Credit Facility
On March 12, 2014, the Company established an unsecured Credit Agreement. This agreement was amended on November 10, 2015 (the “Amended and Restated Credit Agreement”), October 13, 2017 (the “2nd Amendment”), February 25, 2019 (the “3rd Amendment”), and June 17, 2021 (the “Second Amended and Restated Credit Agreement”). The Second Amended and Restated Credit Agreement provides for a $1.50 billion revolving credit facility with a syndicate of lenders, along with an expansion option that will allow the Company, subject to certain requirements, to request an increase in the facility of up to an additional $600.0 million, for a potential total commitment of $2.10 billion. The facility matures on June 17, 2026.
Interest on amounts borrowed under the credit facility is, at the Company’s option, based on (1) a base rate, defined as the greatest of (a) prime rate, (b) Federal Funds rate plus 0.5%, or (c) one-month London Interbank Offered Rate (“LIBOR”) plus 1.0%, plus a spread of 0.00% to 0.30%, or (2) LIBOR multiplied by the statutory rate, plus a spread of 0.805% to 1.30%, in each case plus a facility fee, with such spread and facility fee determined based on the rating of the Company’s non-credit enhanced, senior unsecured long-term debt. Such spreads and such facility fees are further subject to sustainability adjustments as described in the Second Amended and Restated Credit Agreement, in each case based on the Company’s performance of certain energy savings and health and safety standards metrics. Principal and any accrued and unpaid interest is due and payable upon maturity. Additionally, the Company will pay the lenders a quarterly commitment fee that varies based on the Company’s credit rating. The Second Amended and Restated Credit Agreement incorporates provisions for the replacement of LIBOR or other reference rates with alternative reference rates under certain circumstances, including when, or if, such reference rates cease to be available. The Second Amended and Restated Credit Agreement contains affirmative covenants, negative covenants, financial covenants, and events of default. As of June 26, 2022, the Company had no borrowings outstanding under the credit facility and was in compliance with all financial covenants.
Commercial Paper Program
On November 13, 2017, the Company established a commercial paper program (the “CP Program”) under which the Company may issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate principal amount of $1.25 billion. In July 2021, the Company amended the CP Program size to a maximum aggregate amount outstanding at any time of $1.50 billion. The net proceeds from the CP Program will be used for general corporate purposes, including repurchases of the Company’s Common Stock from time to time under the Company’s stock repurchase program. Amounts available under the CP Program may be
Lam Research Corporation 2022 10-K 63
re-borrowed. The CP Program is backstopped by the Company’s Revolving Credit Arrangement. As of June 26, 2022, the Company had no outstanding borrowings under the CP Program.
Interest Cost
The following table presents the amount of interest cost recognized relating to both the contractual interest coupon and amortization of the debt discount, issuance costs, and effective portion of interest rate contracts with respect to the Senior Notes, convertible notes, and the revolving credit facility during the fiscal years ended June 26, 2022, June 27, 2021, and June 28, 2020.
| | | | | | | | | | | | | | | | | |
| Year Ended |
| June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| | (in thousands) |
| Contractual interest coupon | $ | 175,128 | | | $ | 197,367 | | | $ | 169,483 | |
| Amortization of interest discount | 2,767 | | | 3,934 | | | 4,280 | |
| Amortization of issuance costs | 1,351 | | | 1,639 | | | 1,632 | |
| Effect of interest rate contracts, net | 2,455 | | | 2,070 | | | 1,037 | |
| Total interest cost recognized | $ | 181,701 | | | $ | 205,010 | | | $ | 176,432 | |
| | | | | |
Note 15: Leases
The Company leases certain office spaces, manufacturing and warehouse spaces, equipment, and vehicles. While the majority of the Company’s lease arrangements are operating leases, the Company has certain leases that qualify as finance leases.
The components of lease expense were as follows for the years ended June 26, 2022, June 27, 2021, and June 28, 2020:
| | | | | | | | | | | | | | | | | |
| Year Ended |
| June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| (in thousands) |
| Financing lease cost: | | | | | |
| Amortization of right-of-use assets | $ | 7,439 | | | $ | 7,131 | | | $ | 3,613 | |
| Interest on lease liabilities | 658 | | | 697 | | | 506 | |
| Total finance lease cost | $ | 8,097 | | | $ | 7,828 | | | $ | 4,119 | |
| | | | | |
| Operating lease cost | $ | 69,250 | | | $ | 51,519 | | | $ | 46,101 | |
| Variable lease cost | 259,041 | | | 219,040 | | | 91,851 | |
Variable lease payments are expensed as incurred and are not included within the right of use asset and lease liability calculation. Variable lease payments primarily include costs associated with the Company’s third-party logistics arrangements that contain one or more embedded leases. Variable lease costs will fluctuate based on factory output and material receipt volumes. Short-term rental expense, for agreements less than one year in duration, were immaterial for the twelve months ended June 26, 2022, June 27, 2021, and June 28, 2020, respectively.
Supplemental cash flow information related to leases was as follows as of June 26, 2022, June 27, 2021, and June 28, 2020:
| | | | | | | | | | | | | | | | | |
| Year Ended |
| June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| (in thousands) |
| Cash paid for amounts included in the measurement of lease liabilities: | | | | | |
| Operating cash flows paid for operating leases | $ | 64,808 | | | $ | 63,895 | | | $ | 50,223 | |
| Financing cash flows paid for principal portion of finance leases | 11,513 | | | 5,952 | | | 3,539 | |
| | | | | |
| Right-of-use assets obtained in exchange for lease obligations: | | | | | |
| Operating leases | $ | 121,580 | | | $ | 48,993 | | | $ | 108,816 | |
| Finance leases | 13,868 | | | 29,497 | | | 3,019 | |
Lam Research Corporation 2022 10-K 64
Supplemental balance sheet information related to leases were as follows as of June 26, 2022 and June 27, 2021:
| | | | | | | | | | | |
| June 26,
2022 | | June 27,
2021 |
| (in thousands) |
| Operating leases | | | |
| Other assets | $ | 226,648 | | | $ | 173,784 | |
| | | |
| Accrued expenses and other current liabilities | $ | 54,110 | | | $ | 45,310 | |
| Other long-term liabilities | 164,613 | | | 118,385 | |
| Total operating lease liabilities | $ | 218,723 | | | $ | 163,695 | |
| | | |
| Finance Leases | | | |
| Property and Equipment, net | $ | 42,153 | | | $ | 44,054 | |
| | | |
| Current portion of long-term debt and lease liabilities | $ | 7,381 | | | $ | 11,349 | |
| Long-term debt and lease liabilities, less current portion | 35,990 | | | 29,398 | |
| Total finance lease liabilities | $ | 43,371 | | | $ | 40,747 | |
| | | |
| | | | | | | | | | | | | | | | | | | | | | | |
| June 26, 2022 | | June 27, 2021 |
| Weighted-Average Remaining Lease Term | | Weighted-Average Discount Rate | | Weighted-Average Remaining Lease Term | | Weighted-Average Discount Rate |
| (in years) | | | | (in years) | | |
| Operating leases | 5.4 | | 3.05 | % | | 5.5 | | 2.30 | % |
| Finance leases | 6.4 | | 2.01 | % | | 5.3 | | 1.69 | % |
As of June 26, 2022, the maturities of lease liabilities are as follows:
| | | | | | | | | | | |
| Operating Leases | | Finance Leases |
| (in thousands) |
| 2023 | $ | 58,785 | | | $ | 8,094 | |
| 2024 | 46,383 | | | 7,861 | |
| 2025 | 34,910 | | | 7,124 | |
| 2026 | 28,305 | | | 7,165 | |
| 2027 | 21,643 | | | 6,790 | |
| Thereafter | 50,754 | | | 9,657 | |
| Total lease payments | $ | 240,780 | | | $ | 46,691 | |
| Less imputed interest | (22,057) | | | (3,320) | |
| Total | $ | 218,723 | | | $ | 43,371 | |
| | | |
Selected Leases and Related Guarantees
The Company leases the majority of its administrative, research and development and manufacturing facilities, regional sales/service offices, and certain equipment under non-cancelable leases. Certain of the Company’s facility leases for buildings located at its Fremont, California headquarters; Tualatin, Oregon campus; and certain other facility leases provide the Company with options to extend the leases for additional periods or to purchase the facilities. Certain of the Company’s facility leases provide for periodic rent increases based on the general rate of inflation.
The Company has finance leases for certain improved properties in Fremont and Livermore, California (the “California Facility Leases”). The Company is required to maintain cash collateral in an aggregate of approximately $250 million in separate interest-bearing accounts as security for the Company’s obligations. These amounts are recorded with other restricted cash and investments in the Company’s Consolidated Balance Sheet as of June 26, 2022 and June 27, 2021.
Lam Research Corporation 2022 10-K 65
During the seven-year term of the California Facility Leases and when the terms of the California Facility Leases expire, the property subject to the California Facility Leases may be re-marketed. The Company has guaranteed to the lessor that each property will have a certain minimum residual value. The aggregate maximum guarantee made by the Company under the California Facility Leases is $298.4 million.
Note 16: Retirement and Deferred Compensation Plans
Employee Savings and Retirement Plan
The Company maintains a 401(k) retirement savings plan for its eligible employees in the United States. Each participant in the plan may elect to contribute from 1% to 75% of annual eligible earnings to the plan, subject to statutory limitations. The Company makes matching employee contributions in cash to the plan at the rate of 50% of the first 6% of earnings contributed. Employees participating in the 401(k) retirement savings plan are fully vested in the Company matching contributions, and investments are directed by participants. The Company made matching contributions of $32.6 million, $26.9 million, and $23.6 million, in fiscal years 2022, 2021, and 2020, respectively.
Deferred Compensation Arrangements
The Company has an unfunded, non-qualified deferred compensation plan whereby executives may defer a portion of their compensation. Participants earn a return on their deferred compensation based on their allocation of their account balance among various mutual funds. The Company controls the investment of these funds, and the participants remain general creditors of the Company. Participants are able to elect the payment of benefits on a specified date at least three years after the opening of a deferral sub-account or upon retirement. Distributions are made in the form of lump sum or annual installments over a period of up to 20 years as elected by the participant. If no alternate election has been made, a lump sum payment will be made upon termination of a participant’s employment with the Company. As of June 26, 2022, and June 27, 2021, the liability of the Company to the plan participants was $280.0 million and $297.3 million, respectively, which was recorded in accrued expenses and other current liabilities and other long-term liabilities on the Consolidated Balance Sheets. As of June 26, 2022, and June 27, 2021, the Company had investments in the aggregate amount of $291.3 million and $313.9 million, respectively, which correlate to the deferred compensation obligations, which were recorded in other assets on the Consolidated Balance Sheets.
Post-Retirement Healthcare Plan
The Company maintains a post-retirement healthcare plan for certain executive and director retirees. Coverage continues through the duration of the lifetime of the retiree or the retiree’s spouse, whichever is longer. The benefit obligation was $31.2 million and $40.1 million as of June 26, 2022, and June 27, 2021, respectively.
Note 17: Commitments and Contingencies
The Company has certain obligations to make future payments under various contracts; some of these are recorded on its balance sheet and some are not. Obligations that are recorded on the Company’s balance sheet include the Company’s operating and finance lease obligations. Obligations that are not recorded on the Company’s balance sheet include contractual relationships for purchase obligations and certain guarantees. The Company’s commitments relating to off-balance sheet agreements are included in the tables below. These amounts exclude $561.2 million of liabilities related to uncertain tax positions (see Note 7 - Income Taxes for further discussion) as of the end of the fiscal year because the Company is unable to reasonably estimate the ultimate amount or time of settlement. Other Guarantees
The Company has issued certain indemnifications to its lessors for taxes and general liability under some of its agreements. The Company has entered into insurance contracts that are intended to limit its exposure to such indemnifications. As of June 26, 2022, the Company had not recorded any liability on its Consolidated Financial Statements in connection with these indemnifications, as it does not believe that it is probable that any material amounts will be paid under these guarantees.
Generally, the Company indemnifies, under pre-determined conditions and limitations, its customers for infringement of third-party intellectual property rights by the Company’s products or services. The Company seeks to limit its liability for such indemnity to an amount not to exceed the sales price of the products or services subject to its indemnification obligations. The Company does not believe that it is probable that any material amounts will be paid under these guarantees.
The Company provides guarantees and standby letters of credit to certain parties as required for certain transactions initiated during the ordinary course of business. As of June 26, 2022, the maximum potential amount of future payments that the Company could be required to make under these arrangements and letters of credit was $95.1 million. The Company does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be required to be paid.
In addition, the Company has entered into indemnification agreements with its directors, officers and certain other employees, consistent with its Bylaws and Certificate of Incorporation; and under local law, the Company may be required to provide indemnification to its employees for actions within the scope of their employment. Although the Company maintains insurance contracts that cover some of the potential liability associated with these indemnification agreements, there is no guarantee that all
Lam Research Corporation 2022 10-K 66
such liabilities will be covered. The Company does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be required to be paid under such indemnification agreements or statutory obligations.
Purchase Obligations
Purchase obligations consist of non-cancelable significant contractual obligations either on an annual basis or over multi-year periods. The contractual cash obligations and commitments table presented below contains the Company’s minimum obligations at June 26, 2022, under these arrangements and others. For obligations with cancellation provisions, the amounts included in the following table were limited to the non-cancelable portion of the agreement terms or the minimum cancellation fee. Actual expenditures will vary based on the volume of transactions and length of contractual service provided.
The Company’s commitments related to these agreements as of June 26, 2022, were as follows:
| | | | | |
| Payments Due by Fiscal Year: | Purchase
Obligations |
| (in thousands) |
| 2023 | $ | 1,121,362 | |
| 2024 | 43,330 | |
| 2025 | 43,330 | |
| 2026 | 4,319 | |
| 2027 | 4,319 | |
| Thereafter | 1,293 | |
| Total | $ | 1,217,953 | |
| |
Transition Tax Liability
On December 22, 2017, the “Tax Cuts & Jobs Act” was signed into law, among other items, this U.S. tax reform assessed a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred. As a result the Company recognized a total transition tax of $868.4 million and elected to pay the one-time tax over a period of 8 years, commencing in the twelve months ended June 30, 2019.
The Company’s remaining obligation related to this arrangement as of June 26, 2022, were as follows:
| | | | | |
Payments Due by Fiscal Year (1): | Transition Tax |
| (in thousands) |
| 2023 | $ | 69,469 | |
| 2024 | 130,254 | |
| 2025 | 173,672 | |
| 2026 | 217,090 | |
| |
| |
| Total | $ | 590,485 | |
| |
(1) The Company may choose to apply existing tax credits, thereby reducing the actual cash payment.
Warranties
The Company provides standard warranties on its systems. The liability amount is based on actual historical warranty spending activity by type of system, customer, and geographic region, modified for any known differences such as the impact of system reliability improvements. As of June 26, 2022, warranty reserves totaling $24.0 million were recognized in other long-term liabilities, the remainder were included in accrued expenses and other current liabilities in the Company’s Consolidated Balance Sheets.
Lam Research Corporation 2022 10-K 67
Changes in the Company’s product warranty reserves were as follows:
| | | | | | | | | | | | |
| | Year Ended | |
June 26,
2022 | | June 27,
2021 | |
| | (in thousands) | |
| Balance at beginning of period | $ | 191,758 | | | $ | 129,197 | | |
| Warranties issued during the period | 295,167 | | | 229,026 | | |
| Settlements made during the period | (272,954) | | | (172,759) | | |
| Changes in liability for warranties issued during the period | 14,951 | | | — | | |
| Changes in liability for pre-existing warranties | 27,336 | | | 6,294 | | |
| Balance at end of period | $ | 256,258 | | | $ | 191,758 | | |
| | | | |
Legal Proceedings
While the Company is not currently a party to any legal proceedings that it believes material, the Company is either a defendant or plaintiff in various actions that have arisen from time to time in the normal course of business, including intellectual property claims. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. Based on current information, the Company does not believe that a material loss from known matters is probable and therefore has not recorded an accrual of any material amount for litigation or other contingencies related to existing legal proceedings.
Note 18: Stock Repurchase Program
In May 2022, the Board of Directors authorized the Company to repurchase up to an additional $5.0 billion of Common Stock; this authorization supplements the remaining balances from any prior authorizations. These repurchases can be conducted on the open market or as private purchases and may include the use of derivative contracts with large financial institutions, in all cases subject to compliance with applicable law. This repurchase program has no termination date and may be suspended or discontinued at any time.
Repurchases under the repurchase program were as follows during the periods indicated:
| | | | | | | | | | | | | | | | | | | | | | | |
| Period | Total Number
of Shares
Repurchased | | Total
Cost of
Repurchase | | Average
Price Paid
Per Share(1) | | Amount Available
Under Repurchase
Program |
| | (in thousands, except per share data) |
| Available balance as of June 27, 2021 | | | | | | | $ | 4,222,220 | |
| Quarter ended September 26, 2021 | 1,725 | | | $ | 1,209,744 | | | $ | 608.98 | | | $ | 3,012,476 | |
| Quarter ended December 26, 2021 | 677 | | | $ | 429,983 | | | $ | 634.74 | | | $ | 2,582,493 | |
| Quarter ended March 27, 2022 | 2,007 | | | $ | 1,200,206 | | | $ | 609.61 | | | $ | 1,382,287 | |
Board authorization, $5 billion increase, May 2022 | | | | | | | $ | 6,382,287 | |
| Quarter ended June 26, 2022 | 1,912 | | (2) | $ | 867,651 | | | $ | 485.31 | | | $ | 5,514,636 | |
(1) Average price paid per share excludes the effect of accelerated share repurchases. See additional disclosure below regarding the Company’s accelerated share repurchase activity during the fiscal year.
(2) Includes shares received at final settlement of accelerated share repurchase agreements; see additional disclosures below regarding the Company’s accelerated share repurchase activity during the fiscal year.
In addition to the shares repurchased under the Board-authorized repurchase program shown above, the Company acquired 253 thousand shares at a total cost of $138.1 million during the 12 months ended June 26, 2022, which the Company withheld through net settlements to cover minimum tax withholding obligations upon the vesting of restricted stock unit awards granted under the Company’s equity compensation plans. The shares retained by the Company through these net share settlements are not a part of the Board-authorized repurchase program but instead are authorized under the Company’s equity compensation plan.
Accelerated Share Repurchase Agreements
On June 2, 2022, the Company entered into an accelerated share repurchase agreement (the "June 2022 ASR") with two financial institutions to repurchase a total of $500 million of Common Stock. The Company took an initial delivery of approximately 717 thousand shares, which represented 75% of the prepayment amount divided by our closing stock price on June 2, 2022. The total number of shares received under the June 2022 ASR will be based upon the average daily volume weighted average price of the Company’s Common Stock during the repurchase period, less an agreed upon discount. Final settlement of the June 2022 ASR will between August 18, 2022 and November 4, 2022.
Lam Research Corporation 2022 10-K 68
On February 15, 2022, the Company entered into an accelerated share repurchase agreement (the “February 2022 ASR") with two financial institutions to repurchase a total of $600 million of Common Stock. The Company took an initial delivery of approximately 758 thousand shares, which represented 75% of the prepayment amount divided by the Company’s closing stock price on February 15, 2022. The total number of shares received under the February 2022 ASR was based upon the average daily volume weighted average price of the Company’s Common Stock during the repurchase period, less an agreed upon discount. Final settlement of the February 2022 ASR occurred in May 2022, resulting in the receipt of approximately 438 thousand additional shares, which yielded a weighted-average share price of $502.06 for the transaction period.
On August 31, 2021, the Company entered into an accelerated share repurchase agreement (the “August 2021 ASR") with two financial institutions to repurchase a total of $650 million of Common Stock. The Company took an initial delivery of approximately 806 thousand shares, which represented 75% of the prepayment amount divided by the Company’s closing stock price on August 31, 2021. The total number of shares received under the August 2021 ASR was based upon the average daily volume weighted average price of the Company’s Common Stock during the repurchase period, less an agreed upon discount. Final settlement of the August 2021 ASR occurred in January 2022, resulting in the receipt of approximately 265 thousand additional shares, which yielded a weighted-average share price of $606.71 for the transaction period.
Note 19: Comprehensive Income (Loss)
The components of accumulated other comprehensive loss, net of tax at the end of June 26, 2022, as well as the activity during the fiscal year ended June 26, 2022, were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Accumulated
Foreign
Currency
Translation
Adjustment | | Accumulated
Unrealized
Gain or
Loss on
Cash Flow
Hedges | | Accumulated
Unrealized
Holding
Gain or
Loss on
Available-For-
Sale
Investments | | Accumulated
Unrealized
Components
of Defined
Benefit Plans | | Total |
| | (in thousands) |
| Balance as of June 27, 2021 | $ | (31,413) | | | $ | (14,125) | | | $ | 1,611 | | | $ | (20,201) | | | $ | (64,128) | |
| Other comprehensive (loss) income before reclassifications | (50,342) | | | 30,849 | | | (4,638) | | | 5,941 | | | (18,190) | |
(Gains) losses reclassified from accumulated other comprehensive income (loss) to net income (1) | — | | | (29,054) | | | 1,390 | | | — | | | (27,664) | |
| Net current-period other comprehensive income (loss) | (50,342) | | | 1,795 | | | (3,248) | | | 5,941 | | | (45,854) | |
| Balance as of June 26, 2022 | $ | (81,755) | | | $ | (12,330) | | | $ | (1,637) | | | $ | (14,260) | | | $ | (109,982) | |
| | | | | | | | | |
(1)Amount of after-tax gain reclassified from accumulated other comprehensive income into net income is not material individually or in the aggregate, or to any individual location in our Consolidated Statement of Operations.
Tax related to other comprehensive income, and the components thereto, for the years ended June 26, 2022, June 27, 2021, and June 28, 2020 was not material.
Note 20: Segment, Geographic Information, and Major Customers
The Company operates in one reportable business segment: manufacturing and servicing of wafer processing semiconductor manufacturing equipment. The Company’s material operating segments qualify for aggregation due to their customer base and similarities in economic characteristics, nature of products and services, and processes for procurement, manufacturing, and distribution.
The Company operates in seven geographic regions: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. For geographical reporting, revenue is attributed to the geographic location in which the customers’ facilities are located, while long-lived assets; which includes property and equipment, net, and recognized right of use assets reported in other assets in the Consolidated Balance Sheets as of June 26, 2022 and June 27, 2021; are attributed to the geographic locations in which the assets are located.
Lam Research Corporation 2022 10-K 69
Revenues and long-lived assets by geographic region were as follows:
| | | | | | | | | | | | | | | | | |
| | Year Ended |
June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| Revenue: | (in thousands) |
| China | $ | 5,411,502 | | | $ | 5,137,886 | | | $ | 3,083,916 | |
| Korea | 4,037,467 | | | 3,924,685 | | | 2,391,257 | |
| Taiwan | 2,936,482 | | | 2,117,999 | | | 1,906,223 | |
| Japan | 1,624,573 | | | 1,363,907 | | | 954,743 | |
| Southeast Asia | 1,357,648 | | | 945,478 | | | 587,638 | |
| United States | 1,147,346 | | | 672,716 | | | 812,482 | |
| Europe | 712,021 | | | 463,479 | | | 308,477 | |
| Total revenue | $ | 17,227,039 | | | $ | 14,626,150 | | | $ | 10,044,736 | |
| | | | | |
| | | | | | | | | | | | | | | | | |
| June 26,
2022 | | June 27,
2021 | | June 28,
2020 |
| Long-lived assets: | (in thousands) |
| United States | $ | 1,276,274 | | | $ | 1,137,490 | | | $ | 1,052,714 | |
| Southeast Asia | 248,029 | | | 129,881 | | | 31,027 | |
| Korea | 183,809 | | | 62,502 | | | 49,943 | |
| Europe | 77,658 | | | 77,661 | | | 80,297 | |
| Taiwan | 72,845 | | | 47,279 | | | 11,555 | |
| Japan | 8,406 | | | 13,149 | | | 11,826 | |
| China | 7,214 | | | 9,301 | | | 8,720 | |
| $ | 1,874,235 | | | $ | 1,477,263 | | | $ | 1,246,082 | |
| | | | | |
In fiscal year 2022, four customers accounted for approximately 21%, 12%, 12% and 11% of total revenues, respectively. In fiscal year 2021, three customers accounted for approximately 25%, 12% and 10% of total revenues, respectively. In fiscal year 2020, four customers accounted for approximately 24%, 14%, 10%, and 10%, of total revenues, respectively. No other customers accounted for more than 10% of total revenues.
Lam Research Corporation 2022 10-K 70